![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Baseline Predictive Tool for Selecting HBeAg-Negative Chronic Hepatitis B Patients Who Have a High Probability of Achieving Sustained Immune Control with Peginterferon Alfa-2a
|
|
|
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
P. Lampertico1, V. Rothe2, A. Caputo3, G.V. Papatheodoridis4
1AM & A Migliavacca Center for Liver Disease, 1st Gastroenterology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy;
2IST GmbH, Mannheim, Germany; 3Roche S.p.A., Monza, Italy; 4Department of Gastroenterology, Athens University Medical School, Laiko General Hospital, Athens, Greece
![AASLD1.gif](../images/010915/010915-4/AASLD1.gif)
![AASLD2.gif](../images/010915/010915-4/AASLD2.gif)
![AASLD3.gif](../images/010915/010915-4/AASLD3.gif)
![AASLD4.gif](../images/010915/010915-4/AASLD4.gif)
![AASLD5.gif](../images/010915/010915-4/AASLD5.gif)
![AASLD6.gif](../images/010915/010915-4/AASLD6.gif)
![AASLD7.gif](../images/010915/010915-4/AASLD7.gif)
![AASLD8.gif](../images/010915/010915-4/AASLD8.gif)
![AASLD9.gif](../images/010915/010915-4/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|